Related Experiment Video
Updated: Sep 25, 2025

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Urolithin A Nanoparticle Therapy for Cisplatin-Induced Acute Kidney Injury
M N V Ravi Kumar1,2,3,4,5,6
1College of Community Health Sciences, The University of Alabama, Tuscaloosa, Alabama, USA.
Abstract:
Cisplatin continues to be one of the frontline cytotoxic drugs. However, cisplatin-induced acute kidney injury (AKI) remains a major unmet medical need without any approved pharmacological interventions. The involvement of reactive oxygen species generation and activation of inflammatory and apoptotic pathways in the pathogenesis of cisplatin-induced AKI prompts the use of natural anti-inflammatory compounds. In this context, resolution of inflammation using natural antioxidant and anti-inflammatory such as urolithin A (UA) could prove beneficial. In the end, testing such combinations in models to eliminate the possibility that UA stimulates tumor growth or compromises the potency of cisplatin could prove useful for clinical translation of adjuvant therapies.
Insights
Urolithin A, a natural anti-inflammatory compound, may help prevent cisplatin-induced acute kidney injury (AKI). Further research is needed to confirm its efficacy and safety as an adjuvant therapy.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Cisplatin is a vital chemotherapy drug but causes acute kidney injury (AKI), a significant clinical challenge.
- Current treatments for cisplatin-induced AKI are lacking, necessitating novel therapeutic strategies.
- Reactive oxygen species, inflammation, and apoptosis are key mechanisms in cisplatin nephrotoxicity.
Purpose of the Study:
- To explore the potential of urolithin A (UA) as a renoprotective agent against cisplatin-induced AKI.
- To investigate UA's antioxidant and anti-inflammatory properties for mitigating cisplatin nephrotoxicity.
- To assess the feasibility of combining UA with cisplatin for cancer therapy.
Main Methods:
- Preclinical models of cisplatin-induced nephrotoxicity were utilized.
- The antioxidant and anti-inflammatory effects of urolithin A were evaluated.
- Potential interactions between urolithin A and cisplatin were examined.
Main Results:
- Urolithin A demonstrated antioxidant and anti-inflammatory properties relevant to AKI.
- Preliminary data suggest UA may offer protection against cisplatin-induced kidney damage.
- Further studies are required to validate UA's role in combination therapy.
Conclusions:
- Urolithin A presents a promising natural compound for managing cisplatin-induced AKI.
- Its anti-inflammatory and antioxidant actions warrant further investigation for clinical application.
- Future research should focus on safety and efficacy in combination with cisplatin therapy.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi VI: Surgical Management
Acute Kidney Injury V: Interprofessional Care
Kidney Transplant II: Surgical Procedure

